



# MARKET RELEASE

10 November 2014

**Neuren Pharmaceuticals Limited**

**TRADING HALT**

The securities of Neuren Pharmaceuticals Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 12 November 2014 or when the announcement is released to the market.

Security Code:        NEU

Elvis Onyura  
Senior Adviser, Listings Compliance (Sydney)

10 November 2014

Mr Elvis Onyura  
Senior Adviser, Listings Compliance (Sydney)  
ASX Compliance Pty Limited  
20 Bridge Street  
Sydney NSW 2000

By Email

Dear Elvis

**TRADING HALT REQUEST**

The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request a halt in trading of the Company's securities, effective until market opening on 12 November 2014, or an earlier announcement by the Company.

The trading halt is requested pending an announcement regarding Neuren's Phase 2 trial of NNZ-2566 in Rett Syndrome.

The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely



Jon Pilcher  
CFO & Company Secretary